Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices (vol 68, pg 1074, 2019)

被引：0
|
作者：
Bennett, Nancy [1 ]
Farley, Monica [2 ,3 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY 14627 USA
[2] Vet Affairs Med Ctr, Decatur, GA 30033 USA
[3] Emory Univ, Dept Med, Atlanta, GA 30322 USA
来源：
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT | 2020年 / 68卷 / 51-52期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：1195 / 1195
页数：1
相关论文
共 50 条
  • [41] Immunogenicity and Immunological Memory Induced by the 13-Valent Pneumococcal Conjugate Followed by the 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
    Farmaki, Paraskevi F.
    Chini, Maria C.
    Mangafas, Nikolaos M.
    Tzanoudaki, Marianna T.
    Piperi, Christina P.
    Lazanas, Maries Z.
    Spoulou, Vane S.
    JOURNAL OF INFECTIOUS DISEASES, 2018, 218 (01): : 26 - 34
  • [42] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
    Malene, B. Mikkelsen
    Oyvind, Husby
    Tor, Molden
    David, N. Mwaura
    Jens, Olsen
    Nanna, V. Kristensen
    Jeffrey, Vietri
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [43] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
    Mikkelsen Malene B
    Husby Oyvind
    Molden Tor
    Mwaura David N
    Olsen Jens
    Kristensen Nanna V
    Vietri Jeffrey
    Cost Effectiveness and Resource Allocation, 21
  • [44] Pneumococcal vaccine uptake among Medicare Beneficiaries aged >65 years following the shared clinical decision-making recommendation for 13-valent pneumococcal conjugate vaccine in 2019
    Vietri, Jeffrey
    Sato, Reiko
    Averin, Ahuva
    Weycker, Derek
    Kumar, Mahesh
    Prasad, Sapna
    Chilson, Erica
    VACCINE, 2023, 41 (36) : 5211 - 5215
  • [45] Use of 21-Valent Pneumococcal Conjugate Vaccine Among US Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024
    Kobayashi, Miwako
    Leidner, Andrew J.
    Gierke, Ryan
    Farrar, Jennifer L.
    Morgan, Rebecca L.
    Campos-Outcalt, Doug
    Schechter, Robert
    Poehling, Katherine A.
    Long, Sarah S.
    Loehr, Jamie
    Cohen, Adam L.
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2024, 73 (36): : 793 - 798
  • [46] Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
    Jackson, Lisa A.
    El Sahly, Hana M.
    George, Sarah
    Winokur, Patricia
    Edwards, Kathryn
    Brady, Rebecca C.
    Rouphael, Nadine
    Keitel, Wendy A.
    Mulligan, Mark J.
    Burton, Robert L.
    Nakamura, Aya
    Ferreria, Jennifer
    Nahm, Moon H.
    VACCINE, 2018, 36 (05) : 606 - 614
  • [47] Use of 15-Valent Pneumococcal Conjugate Vaccine Among US Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022
    Kobayashi, Miwako
    Farrar, Jennifer L.
    Gierke, Ryan
    Leidner, Andrew J.
    Campos-Outcalt, Doug
    Morgan, Rebecca L.
    Long, Sarah S.
    Poehling, Katherine A.
    Cohen, Adam L.
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2022, 71 (37): : 1174 - 1181
  • [48] Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed): In Older Adults (vol 72, pg 1243, 2012)
    Sanford, M.
    DRUGS, 2012, 72 (16) : 2176 - 2176
  • [49] Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed)A Guide to Its Use in Older Adults
    Lesley J. Scott
    Mark Sanford
    Drugs & Aging, 2012, 29 : 847 - 855
  • [50] Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) A Guide to Its Use in Older Adults
    Scott, Lesley J.
    Sanford, Mark
    DRUGS & AGING, 2012, 29 (10) : 847 - 855
12345